The MITEF Spain Jury has reached this decision considering their business model, technology, market potential and evolution, and the team itself.They have developed a technology that is capable of sequencing RNA, from a small blood sample, and associating the expression of genes in more than 320 metabolic pathways that act as biomarkers of the parameters of the individual's body, analyzing all those variations that are out of the ordinary to improve and prevent health problems.
